Phaseline

Targets › TYK2

TYK2 (Non-receptor tyrosine-protein kinase TYK2): drug programs, companies and trials

16 programs from 15 companies in 202 trials: 85 Phase 2, 52 Phase 3, 42 Phase 1, 23 Phase 4; Immunology, Other, Oncology; next expected readout Nov 2026.

Non-membrane spanning protein tyrosine kinase involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity. Plays both structural and catalytic roles in numerous interleukins and interferons (IFN-alpha/beta) signaling. (UniProt, P29597)

Open in Phaseline: the race on TYK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbDeucravacitinib
Tyrosine-protein kinase TYK2 negative allosteric modulator
TYK2Phase 4Systemic Lupus Erythematosus (SLE); Psoriatic Arthritis; Sjögren's Syndrome; Systemic Lupus Erythematosus …Nov 2026
TakedaTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 4Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus …Jul 2027
EisaiFilgotinib Maleate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 4Ulcerative ColitisNov 2027
IncyteRuxolitinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) …Nov 2026
AbbVieUpadacitinib
Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
TYK2, JAK3, JAK2, JAK1Phase 3Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease …Nov 2026
InventisBio[14C] D-2570
TYK2 pseudokinase domain inhibitor
TYK2Phase 3Plaque Psoriasis; UC - Ulcerative Colitis; Psoriasis; PsA (Psoriatic Arthritis) …Nov 2026
LEO PharmaDelgocitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; VitiligoDec 2026
Pfizertofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Ulcerative ColitisMar 2027
Sun Pharmaceutical IndustriesDeuruxolitinib Phosphate (CTP-543)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3Alopecia AreataMay 2027
AlfasigmaFilgotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 3Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis …Jun 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQH3906 Capsules
Highly selective TYK2 allosteric inhibitor targeting the JH2 domain, blocking IL-23 and Ty
TYK2Phase 3Psoriasis; Psoriatic Arthritis; Inflammatory Bowel DiseasesJul 2027
AlumisEnvudeucitinib (ESK-001)
Oral PROTAC degrader of Ikaros (IKZF1)
IKZF1, TYK2Phase 3Plaque Psoriasis; SLESep 2027
M.D. Anderson Cancer CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia …Jan 2027
City of Hope Medical CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System NeoplasmMar 2027
Shixiu WuJAK Inhibitors
Janus kinase inhibitors
JAK1, JAK2, JAK3, TYK2Phase 2Immune Checkpoint Inhibitors (ICI)-Related Dermatitis–
AbbVieTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 1Healthy VolunteersDec 2026

Conditions

Plaque Psoriasis (7) Ulcerative Colitis (6) Rheumatoid Arthritis (6) Atopic Dermatitis (6) Vitiligo (5) Alopecia Areata (4) Hidradenitis Suppurativa (4) Acute Lymphoblastic Leukemia (4) Psoriatic Arthritis (3) Systemic Lupus Erythematosus (3) Psoriasis (3) Rheumatoid Arthritis (RA (3)

Modalities

small molecule (15), mixed (1)

Companies

AbbVie (2) Sun Pharmaceutical Industries (1) Alumis (1) Bristol-Myers Squibb (1) Alfasigma (1) Takeda (1) Incyte (1) LEO Pharma (1) Eisai (1) InventisBio (1) City of Hope Medical Center (1) Shixiu Wu (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) M.D. Anderson Cancer Center (1) Pfizer (1)

Related targets

JAK1 (12) JAK2 (12) JAK3 (12) IKZF1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.